Literature DB >> 2107097

The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum.

M I Lethem1, S L James, C Marriott, J F Burke.   

Abstract

The relative importance of host and bacteria-derived deoxyribonucleic acid (DNA) in the increased viscoelasticity of purulent sputum in cystic fibrosis (CF) and other airway diseases is unclear. We report the identification of the DNA associated with mucus glycoproteins purified from the purulent sputum of 9 patients with CF. Mucus glycoproteins were purified from CF sputum by gel exclusion chromatography and the co-purifying DNA isolated by phenol extraction. Electrophoresis indicated that the DNA preparations had a size of approximately 300 to greater than 50,000 bases. The origin of the DNA was determined by slot blotting and subsequent hybridization with 32P-labelled DNA probes specific for human DNA sequences and those from bacterial species commonly isolated from CF sputum. The results indicated that in all cases the DNA was almost entirely human in origin. This implies that it is the patient's own DNA which may contribute to the rheological abnormalities of CF sputum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107097

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  54 in total

Review 1.  Cystic fibrosis: an inherited disease affecting mucin-producing organs.

Authors:  Camille Ehre; Caroline Ridley; David J Thornton
Journal:  Int J Biochem Cell Biol       Date:  2014-03-28       Impact factor: 5.085

2.  Chelation of Membrane-Bound Cations by Extracellular DNA Activates the Type VI Secretion System in Pseudomonas aeruginosa.

Authors:  Mike Wilton; Megan J Q Wong; Le Tang; Xiaoye Liang; Richard Moore; Michael D Parkins; Shawn Lewenza; Tao G Dong
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

3.  Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Baoleri Lee; Janus A J Haagensen; Oana Ciofu; Jens Bo Andersen; Niels Høiby; Søren Molin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 4.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 5.  Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis.

Authors:  S P Conway; A Watson
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

6.  Cytochrome c release is required for phosphatidylserine peroxidation during Fas-triggered apoptosis in lung epithelial A549 cells.

Authors:  Jianfei Jiang; Vidisha Kini; Natalia Belikova; Behice F Serinkan; Grigory G Borisenko; Yulia Y Tyurina; Vladimir A Tyurin; Valerian E Kagan
Journal:  Lipids       Date:  2004-11       Impact factor: 1.880

7.  Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease.

Authors:  C A Sheils; J Käs; W Travassos; P G Allen; P A Janmey; M E Wohl; T P Stossel
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

8.  Mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in C127 cells: possible relevance to cystic fibrosis.

Authors:  R A Gottlieb; A Dosanjh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

9.  Abundant DNase I-sensitive bacterial DNA in healthy porcine lungs and its implications for the lung microbiome.

Authors:  Alejandro A Pezzulo; Patrick H Kelly; Boulos S Nassar; Cedric J Rutland; Nicholas D Gansemer; Cassie L Dohrn; Andrew J Costello; David A Stoltz; Joseph Zabner
Journal:  Appl Environ Microbiol       Date:  2013-07-19       Impact factor: 4.792

10.  Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.

Authors:  Misagh Alipour; Zacharias E Suntres; Majed Halwani; Ali O Azghani; Abdelwahab Omri
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.